FGF-21 fusion proteins
The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
1. A heterologous fusion protein comprising a first polypeptide fused to a second polypeptide wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide via a linker and wherein the first polypeptide is a human FGF-21 mutein selected from the group consisting of:
(a) SEQ ID NO:1 having mutations Leu118Cys-Ala134Cys;
(b) SEQ ID NO:1 having mutations Leu21Cys-Leu33Cys;
(c) SEQ ID NO:1 having mutations Ala26Cys-Lys122Cys;
(d) SEQ ID NO:1 having mutations Ala31Cys-Gly43Cys;
(e) SEQ ID NO:1 having mutations Leu21Cys-Leu33Cys/Leu118Cys-Ala134Cys;
(f) SEQ ID NO:1 having mutations IIe52Glu-Ser163Glu/Leu 118Cys-Ala134Cys; and
(g) SEQ ID NO:1 having mutations Leu118Cys-Ala134Cys/Ser167Ala;
wherein the second polypeptide is selected from the group consisting of:
(a) the Fc portion of an immunoglobulin;
(b) fragments of the Fc portion of an immunoglobulin;
(c) human albumin; and
(d) fragments of human albumin;
and wherein the linker is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, [SEQ ID NO: 5] 3 , [SEQ ID NO: 5] 4 , [SEQ ID NO:5] 5 , and [SEQ ID NO: 5] 6 .
2. A heterologous fusion protein comprising a first polypeptide fused to a second polypeptide wherein the N-terminus of the first polypeptide is fused to the C-terminus of the second polypeptide via a linker and wherein the first polypeptide is selected from the group consisting of:
(a) the Fc portion of an immunoglobulin;
(b) fragments of the Fc portion of an immunoglobulin;
(c) human albumin; and
(d) fragments of human albumin;
wherein the second polypeptide is a human FGF-21 mutein selected from the group consisting of:
(a) SEQ ID NO:1 having mutations Leu 118Cys-Ala134Cys;
(b) SEQ ID NO:1 having mutations Leu21Cys-Leu33Cys;
(c) SEQ ID NO:1 having mutations Ala26Cys-Lys122Cys;
(d) SEQ ID NO:1 having mutations Ala31Cys-Gly43Cys;
(e) SEQ ID NO:1 having mutations Leu21Cys-Leu33Cys/Leu118Cys-Ala134Cys;
(f) SEQ ID NO:1 having mutations IIe52Glu-Ser163Glu/Leu118Cys-Ala134Cys; and
(g) SEQ ID NO:1 having mutations Leu 118Cys-Ala134Cys/Ser167Ala;
and, wherein the linker is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, [SEQ ID NO: 5] 3 , [SEQ ID NO: 5] 4 , [SEQ ID NO:5] 5 , and [SEQ ID NO: 5] 6 .
3. A heterologous human FGF-21/human IgG4 Fc region fusion protein selected from the group consisting of:
(a) SEQ ID NO:1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO:5 fused to SEQ ID NO: 4 having mutation Ser11Pro, fused in the N-terminal to C-terminal direction;
(b) SEQ ID NO:1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO:5 fused to SEQ ID NO: 4 having mutations Ser11Pro/Phe17Ala/Leu18Ala, fused in the N-terminal to C-terminal direction;
(c) SEQ ID NO:1 having mutations Leu 118 Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO:5 fused to SEQ ID NO: 4 having mutations Ser11Pro/Asn80Ala, fused in the N-terminal to C-terminal direction;
(d) SEQ ID NO:1 having mutations Leu118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO:5 fused to SEQ ID NO: 4 having mutations Ser11Pro/Phe17Ala/Leu18Ala/Asn80Ala, fused in the N-terminal to C-terminal direction;
(e) SEQ ID NO: 1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO:6 fused to SEQ ID NO: 4 having mutation Ser11Pro, fused in the N-terminal to C-terminal direction;
(f) SEQ ID NO:1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO:6 fused to SEQ ID NO: 4 having mutations Ser11Pro/Phe17Ala/Leu18Ala, fused in the N-terminal to C-terminal direction;
(g) SEQ ID NO:1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO: 6 fused to SEQ ID NO: 4 having mutations Ser11Pro/Asn80Ala, fused in the N-terminal to C-terminal direction;
(h) SEQ ID NO:1 having mutations Leu118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO: 6 fused to SEQ ID NO: 4 having mutations Ser11Pro/Phe17Ala/Leu18Ala/Asn80Ala, fused in the N-terminal to C-terminal direction;
(i) SEQ ID NO:1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO: 7 fused to SEQ ID NO: 4 having mutation Ser11Pro, fused in the N-terminal to C-terminal direction;
(j) SEQ ID NO:1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO: 7 fused to SEQ ID NO: 4 having mutations Ser11Pro/Phe17Ala/Leu18Ala, fused in the N-terminal to C-terminal direction;
(k) SEQ ID NO: 1 having mutations Leu 118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO: 7 fused to SEQ ID NO: 4 having mutations Ser11Pro/Asn80Ala, fused in the N-terminal to C-terminal direction; and
(l) SEQ ID NO: 1 having mutations Leu118Cys/Ala134Cys/Ser167Ala fused to SEQ ID NO: 7 fused to SEQ ID NO: 4 having mutations Ser11Pro/Phe17Ala/Leu18Ala/Asn80Ala, fused in the N-terminal to C-terminal direction.